Re: Endocrine profile and HPT axis in SSRI-induced male sexual dysfunction

[Guest guest]

The findings are no shock to me. My testosterone tested out as 458 ng/dl at age 26 and I generally feel about 40-50% weaker strength wise than I did before I took Zoloft. I would almost guarantee my testosterone was at least 700 ng/dl pre Zoloft.

[Guest guest]

nice study, maybe PSSD is related to hypogonadism

>

> Evaluation of endocrine profile and hypothalamic-pituitary-testis axis

> in selective serotonin reuptake inhibitor-induced male sexual

> dysfunction

> http://www.ncbi.nlm.nih.gov/pubmed/18626269

> <http://www.ncbi.nlm.nih.gov/pubmed/18626269>

>

[Guest guest]

I just wanted to bump this thread just in case some members missed it because

the title of the topic was changed. This is the first study Ive seen that shows

specifically what SSRI does to our HPTA axis.

Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in

selective serotonin reuptake inhibitor-induced male sexual dysfunction.

Safarinejad MR.

Source

Urology and Nephrology Research Center, Shahid Beheshti University (MS), Tehran,

Iran.

Abstract

PURPOSE:

To evaluate endocrine profile and hypothalamic-pituitary-testis (HPT) axis in

male depressed patients with selective serotonin reuptake inhibitor

(SSRI)-induced sexual dysfunction (SDF).

MATERIALS AND METHODS:

Eighty-six fertile depressed male patients with SSRI-induced SDF, aged 18 to 50

years, were enrolled in the study (group 1). Sixty-two age-matched depressed

fertile patients who currently receive one of the SSRIs but without SDF (group

2), and 68 age-matched healthy fertile men who had never received a psychiatric

diagnosis (group 3) served as controls. Pretreatment evaluation included history

and physical examination and International Index of Erectile Function. Two blood

samples were drawn from each subject at 20-minute intervals for the

determination of the resting levels of the following hormones: luteinizing

hormone (LH), follicle-stimulating hormone (FSH), testosterone, prolactin, and

estradiol. The HPT axis was also assessed using the gonadotropin-releasing

hormone test.

RESULTS:

The prevalence of hormonal abnormalities in groups 1, 2, and 3 were 83.7% (72),

51.6% (32), and 11.8% (7), respectively (P = 0.001 vs group 1 and 0.007 vs group

2). Compared with normal controls, the subjects taking SSRIs had significantly

lower serum levels of LH, FSH, and testosterone. In addition, there were

significantly decreased LH and FSH responses to gonadotropin-releasing hormone

test in groups 1 and 2 compared with normal controls. Of patients in groups 1

and 2, 68 (79.1%) and 27 (43.5%) had elevated serum levels of prolactin (P =

0.0001 vs group 1 and 0.001 vs group 2).

CONCLUSIONS:

Most depressed subjects taking SSRIs with and without SDF had diminished HPT

axis function. This should be replicated in further studies.

>

> Evaluation of endocrine profile and hypothalamic-pituitary-testis axis

> in selective serotonin reuptake inhibitor-induced male sexual

> dysfunction

> http://www.ncbi.nlm.nih.gov/pubmed/18626269

> <http://www.ncbi.nlm.nih.gov/pubmed/18626269>

>